Alcon (ALC) has been gaining from a strong market rebound. The company’s pipeline strength and focus on research and innovation are also impressive. The stock carries a Zacks Rank #2 (Buy) currently.Alcon leads the market in Presbyopia-correcting Intraocular Lens (PCIOLs), with over 60% of the global share and more than 80% share in the United States. In Surgical, the company has maintained a strong share in PCIOLs, solidifying its market-leading position driven by strong demand for products like PanOptix a ...